This report introduces S‑Fusion™, Samsung’s advanced fusion imaging technology, designed to improve precision in liver and prostate cancer procedures by combining real-time ultrasound with MRI, CT, or PET imaging.
For liver cancer, the report explains how S‑Fusion™ for Liver facilitates liver tumor ablation procedures, particularly in patients unsuitable for surgery. It overcomes the limitations of conventional fusion imaging—such as time-consuming, manual registration—by offering auto-registration in four modes: positioning, matching, sweeping, and respiration. These innovations reduce registration time by up to four times while enhancing accuracy, even when tumor boundaries are unclear in ultrasound alone.
For prostate cancer, S‑Fusion™ for Prostate addresses challenges in targeted biopsies caused by prostate deformation during transrectal ultrasound. It combines real-time TRUS with pre-acquired MR images to improve the accuracy of tumor targeting. Key features include auto prostate segmentation, which automatically constructs a 3D prostate volume from MR images; prostate deformation correction, which adjusts for shape changes during the procedure; auto calibration for precise registration; and 3D modeling to guide and document biopsy locations. Clinical studies cited in the report demonstrate significant improvements in registration accuracy and biopsy hit rates using S‑Fusion™ compared to conventional methods.
The report also outlines the clinical relevance of liver and prostate cancers, statistics on incidence and mortality, and the limitations of standard imaging techniques.
In summary, S‑Fusion™ for Liver and Prostate delivers intuitive, fast, and accurate multi-modality fusion imaging, supporting clinicians with enhanced visualization and workflow efficiency during liver ablation and prostate biopsy procedures. The technology exemplifies Samsung Medison’s commitment to advancing diagnostic and interventional ultrasound solutions.
